Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival

Basit Öğe Kaydı
dc.contributor.authorEge, Cigdem Berna
dc.contributor.authorAkbulut, Metin
dc.contributor.authorZekioglu, Osman
dc.contributor.authorOzdemir, Necmettin
dc.date.accessioned2019-10-27T21:35:44Z
dc.date.available2019-10-27T21:35:44Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.description.abstractInhibitors of tumor angiogenesis and metastasis are emerging as important new drug candidates for cancer therapy. Galectin-3 and heparanase have been shown to function in tumor progression and metastatic spread. Both of them exert pleiotropic effects; proliferation, cell migration, differentiation and tissue remodeling. The aim of this study was to investigate heparanase and galectin-3 expression in endometrioid and serous carcinomas of the endometrium and their relation with well-known prognostic factors, in addition to estrogen, progesterone, C-erbB-2, Ki-67 and p53. Sixty-four endometrial cancers, which include 24 serous types, were obtained from previously untreated patients. Immunohistochemical analysis of 64 carcinomas, 20 endometrial hyperplasia (ten of simple hyperplasia and ten of complex atypic hyperplasia) and 20 normal endometrium (ten of proliferative and ten of secretory) was performed. This investigation suggests that the decreased expression of galectin-3 may be involved in the pathogenesis of endometrial carcinomas from normal endometrium to carcinoma. Also down-regulated stromal expression of galectin-3 in endometrial carcinoma may be involved in lymph node metastasis. Further studies on a larger advanced stage (FIGO stage 3-4) endometrial carcinoma group may determine the value of heparanase in the endometrial carcinoma.en_US
dc.description.sponsorship'BAP' comission of Pamukkale UniversityPamukkale University [2008TPF009, 2009KKP073, 2007KRM001]en_US
dc.description.sponsorshipThis work is supported by grant of 'BAP' comission of Pamukkale University, No 2008TPF009. Some of the findings about galectin-3 were presented orally in the 22nd European Pathology Congress and also this presentation was supported in part by grant of 'BAP' comission of Pamukkale University, No 2009KKP073 and 2007KRM001. We thank Dr. Mehmet Zencir and Dr. Ozgur Onal for their contributions in statistical analysis and Mr. Emin Ates for technical assistance.en_US
dc.identifier.doi10.1007/s00404-010-1766-9en_US
dc.identifier.endpage1239en_US
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue5en_US
dc.identifier.pmid21153652en_US
dc.identifier.startpage1231en_US
dc.identifier.urihttps://doi.org/10.1007/s00404-010-1766-9
dc.identifier.urihttps://hdl.handle.net/11454/45921
dc.identifier.volume284en_US
dc.identifier.wosWOS:000295737300026en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofArchives of Gynecology and Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGalectin-3en_US
dc.subjectHeparanaseen_US
dc.subjectSerous endometrial carcinomaen_US
dc.subjectEndometrial hyperplasiaen_US
dc.titleInvestigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survivalen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu